Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

ANDG May 18, 2026

Andersen Global Q1 2026 Earnings Call - Revenue and EBITDA Beat Driven by Pricing Power and Organic Growth

Andersen Global delivered a robust first quarter, with revenue climbing 15.7% to $240.7 million and adjusted EBITDA surging 26.4% to $72.3 million, comfortably beating guidance on both top and bottom ...

  • Revenue reached $240.7 million, up 15.7% year-over-year, exceeding the guidance midpoint by approximately $8.2 million and driven entirely by organic growth.
  • Adjusted EBITDA surged 26.4% to $72.3 million, with margins expanding to 30%, outperforming the 25-26% guidance range by 450 basis points.
  • Revenue per professional jumped 12.7%, reflecting a combination of improved productivity and pricing power, with revenue per hour up 8%.
  • +7 more takeaways
DAC May 18, 2026

Danaos Corporation {Q1} {2026} Earnings Call - Surge in Dry Bulk Yields and Strategic LNG Pivot Amid Geopolitical Shifts

Danaos Corporation reported a solid first quarter of 2026, driven by a dramatic recovery in the dry bulk market and resilient container chartering. Adjusted EPS rose to $6.72, up from $6.04 in the pri...

  • Adjusted EPS reached $6.72, up from $6.04 in Q1 2025, reflecting a $9.1 million increase in adjusted net income.
  • Dry bulk spot market surged, with TCE earnings averaging $24,825 per day, nearly double the $10,500 per day recorded in Q1 2025.
  • Container fleet revenues fell $6.6 million due to lower contracted rates and GAAP accounting adjustments, partially offset by newbuilding additions and improved utilization.
  • +7 more takeaways
BRC May 18, 2026

Brady Corporation Q3 FY2026 Earnings Call - Record EPS and Aggressive Honeywell Acquisition

Brady Corporation delivered a standout quarter with record adjusted EPS of $1.50, up 23% year-over-year, driven by robust 8.2% organic sales growth and expanding gross margins nearing 52%. The results...

  • Record adjusted EPS of $1.50, marking a 23% year-over-year increase and a new quarterly high for the company.
  • Organic sales grew 8.2%, with the Americas and Asia region leading at 10.1% growth, while Europe and Australia returned to growth at 4.5%.
  • Gross profit margin expanded to 51.8%, benefiting from prior cost reduction actions and a favorable product mix, particularly in high-margin wire and identification solutions.
  • +7 more takeaways
LMRI May 18, 2026

Lumexa Imaging Q1 2026 Earnings Call - Advanced Imaging Growth Offsets Seasonal and Weather Headwinds

Lumexa Imaging delivered Q1 2026 results that met expectations, with consolidated revenue of $253 million and adjusted EBITDA of $51.2 million. The quarter was shaped by seasonal dynamics and weather ...

  • Consolidated revenue grew 3% year-over-year to $253 million, while system-wide revenue grew 4%.
  • Advanced modality volumes grew 7% year-over-year, with PET up 23.1% and MRI up 8.2%.
  • Adjusted EBITDA was flat at $51.2 million, impacted by $4 million in seasonal and weather-related volume softness.
  • +7 more takeaways
ONFO May 18, 2026

Onfolio Holdings Q1 2026 Earnings Call - AI-Driven Restructuring Cuts Costs, Secures $100M Equity Facility for Accretive Acquisitions

Onfolio Holdings reported a deliberate revenue contraction in Q1 2026 as it restructured its portfolio to prioritize profitability over top-line growth. The company slashed ad spend at its B2C educati...

  • Revenue fell 34% year-over-year to $1.9 million, reflecting intentional pullbacks in ad spend and operational restructuring rather than organic demand weakness.
  • Operating expenses dropped 30% to $1.8 million as the company consolidated overhead and replaced manual processes with AI-driven workflows in its B2B agency segment.
  • RevenueZen restructuring nearly doubled operating margins to approximately 15% after consolidating operational costs under Eastern Standard and rebuilding core processes using AI.
  • +7 more takeaways
AGPU May 18, 2026

Axe Compute Q1 2026 Earnings Call - $260M Landmark Deal Signals Shift to Asset-Heavy AI Compute Ownership

Axe Compute reported a transitional Q1 2026 with a reported net loss of $7.7 million, driven largely by a $4.3 million non-cash mark-to-market loss on its Aether token holdings. Underlying operating l...

  • Axe Compute reported a Q1 2026 net loss of $7.7 million, primarily due to a $4.3 million non-cash mark-to-market loss on Aether token holdings, while underlying operating losses were $3.4 million.
  • Compute segment revenue was minimal at $35,000 in Q1 2026, down from $110,000 in Q1 2025, as the company transitions away from its legacy drug discovery services business.
  • Contract liabilities for compute services surged to $786,000 at the end of Q1 2026, up from $144,000, reflecting advance payments from customers for future compute capacity.
  • +7 more takeaways
BIDU May 18, 2026

Baidu Q1 2026 Earnings Call - AI Revenue Surpasses Half of Total Business for First Time

Baidu returned to top-line growth in Q1 2026, with total revenue rising 2% year-over-year to CNY 26.0 billion in its general business. The real story, however, lies in the internal shift. AI-powered r...

  • Total revenue for Baidu General Business grew 2% year-over-year to CNY 26.0 billion, marking a return to positive growth after several quarters of decline.
  • AI-powered business revenue surged 49% year-over-year to CNY 13.6 billion, accounting for 52% of total revenue for the first time in company history.
  • AI Cloud Infra revenue accelerated 79% year-over-year, with GPU Cloud revenue jumping 184% year-over-year, driven by strong enterprise demand for training and inference workloads.
  • +7 more takeaways
AII May 18, 2026

American Integrity Insurance Group Q1 2026 Earnings Call - Voluntary Growth Accelerates Amid Florida Legislative Reforms

American Integrity Insurance Group reported Q1 2026 results that underscore a decisive pivot from reliance on Citizens takeouts to durable, voluntary-driven growth. Net income of $19.9 million ($1.02 ...

  • Net income of $19.9 million ($1.02 diluted EPS) reflects normalization after 2025’s elevated Citizens takeout benefits, providing a clearer view of underlying earnings power.
  • Net premiums earned surged 25.7% year-over-year to $82.2 million, driven by voluntary market expansion and a reduction in quota share cession from 40% to 25%.
  • Multi-channel distribution delivered double-digit policy growth: independent agents up 9%, company alliances up nearly 40%, builders up over 38%, and national accounts up over 40%.
  • +7 more takeaways
KURA May 18, 2026

Kura Oncology Q1 2026 Earnings Call - KOMZIFTI Capture 40% of New Patient Starts in First Full Quarter

Kura Oncology’s first full quarter of commercial launch for KOMZIFTI delivered $5.8 million in net product revenue, beating initial expectations and capturing 40% of new patient starts in the NPM1 mut...

  • KOMZIFTI generated $5.8 million in net product revenue in its first full quarter of launch, exceeding early expectations.
  • The company captured 40% of new patient starts in the NPM1 mutant AML market, despite being second to a competitor.
  • Physician adoption is accelerating, evidenced by repeat prescriptions, expanding use across 60 activated accounts, and early switching from other menin inhibitors.
  • +7 more takeaways
CGEN May 18, 2026

Compugen Q1 2026 Earnings Call - COM701 Ovarian Cancer Trial Advances, Financial Runway Extends to 2029

Compugen’s first quarter 2026 results underscore a company executing on its clinical roadmap with a cash runway that comfortably extends into 2029. The core narrative centers on COM701, its PVRIG-targ...

  • COM701, a first-in-class anti-PVRIG antibody, is advancing into earlier-line ovarian cancer treatment via the MAIA-ovarian adaptive platform trial, targeting relapsed platinum-sensitive patients as maintenance therapy.
  • The MAIA-ovarian trial is actively enrolling across U.S., Israeli, and French sites, with management confident in achieving interim median PFS data by Q1 2027.
  • Compugen’s cash runway extends into 2029, supported by $65 million from AstraZeneca in December 2025 and prior licensing revenues, requiring no near-term dilution.
  • +9 more takeaways